Nov 7
Audit or legal opinion
CNINFO
中文
中国国际金融股份有限公司关于南通联亚药业股份有限公司调整募集资金投资项目拟投入募集资金金额的核查意见
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's reports, filings, earnings calls and investor events, most recent first. Search these from Claude or ChatGPT →
联亚药业 listed on Shenzhen Stock Exchange’s ChiNext on 2026-10-15, with 12个 domestically developed products, 9个 China-U.S. co-approved products, and 48个 self-developed products approved by the U.S. FDA.
联亚药业拟公开发行1亿33739563股,占发行后总股本的15%,发行价每股7. 00元;拟募集资金9. 5亿元,投向生产基地建设、研发中心建设、药物研发项目及补充流动资金。